Trial · NCT07218380
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380, Phase 3, Recruiting, Eli Lilly and Company
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract. Trials, record NCT07218380. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07218380
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- NCT number
- NCT07218380
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 450 participants, estimated
- Lead sponsor
- Eli Lilly and Company
- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
- Interventions
- Vepugratinib, Placebo, EV, Pembrolizumab
- First posted
- 2025-10-20
- Last updated
- 2026-10-07
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with treatment-related adverse events related to vepugratinib in combination with EV and pembrolizumab | From baseline up to 90 months | |
| Primary | Safety Lead-in: Overall Response Rate (ORR) | From baseline up to 90 months | ORR by Investigator Assessment. |
| Primary | Progression-free Survival (PFS) | Baseline to Study Completion (estimated as 6 years) | PFS by blinded independent committee review (BICR). |
| Secondary | Safety Lead-in: Disease Control Rate (DCR) | From baseline up to the end of Cycle 2 (each Cycle is 21 days) | DCR by investigator assessment. |
| Secondary | Safety Lead-in: Time to Response (TTR) | From baseline up to 90 months | TTR by investigator assessment. |
| Secondary | Overall Survival (OS) | Baseline to Study Completion (estimated as 6 years) | |
| Secondary | Objective Response Rate (ORR) by BICR | Baseline to Study Completion (estimated as 6 years) | |
| Secondary | Duration of Response (DoR) | Baseline to Study Completion (estimated as 6 years) | DOR by BICR. |
| Secondary | Progression-free Survival (PFS) | Baseline to Study Completion (estimated as 6 years) | PFS by investigator assessment. |
| Secondary | Objective Response Rate (ORR) | Baseline to Study Completion (estimated as 6 years) | Percentage of Participants who Achieve a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)ORR by investigator assessment |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07218380
GET https://conductscience.org/api/trials/v1/NCT07218380/registered